Headlines about Spero Therapeutics (NASDAQ:SPRO) have trended somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Spero Therapeutics earned a daily sentiment score of 0.06 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 49.8622427871252 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the headlines that may have impacted Accern’s rankings:
Get Spero Therapeutics alerts:
Spero Therapeutics (SPRO) PT Set at $30.00 by Oppenheimer (americanbankingnews.com) Spero Therapeutics (SPRO) Lifted to Hold at ValuEngine (americanbankingnews.com) Spero Therapeutics to Present at Bank of America Merrill Lynch Health Care Conference in May (feeds.benzinga.com) Spero Therapeutics to Present at BankofAmericaMerrill Lynch Health Care Conference in May (finance.yahoo.com) Spero Therapeutics’ (SPRO) Buy Rating Reiterated at Cantor Fitzgerald (americanbankingnews.com)
Shares of NASDAQ SPRO traded down $0.24 during trading on Friday, reaching $12.40. The company had a trading volume of 27,413 shares, compared to its average volume of 50,518. Spero Therapeutics has a twelve month low of $9.66 and a twelve month high of $19.00. The stock has a market cap of $178.18 and a price-to-earnings ratio of -0.70.
Spero Therapeutics (NASDAQ:SPRO) last released its quarterly earnings results on Monday, April 2nd. The company reported ($1.59) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.77) by $0.18. The company had revenue of $0.99 million during the quarter, compared to analyst estimates of $0.40 million. analysts forecast that Spero Therapeutics will post -4.44 EPS for the current fiscal year.
A number of analysts have commented on the company. Cantor Fitzgerald set a $27.00 target price on Spero Therapeutics and gave the stock a “buy” rating in a research report on Thursday, April 12th. Oppenheimer reiterated a “buy” rating on shares of Spero Therapeutics in a research report on Tuesday, March 20th. ValuEngine raised Spero Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday. Finally, Zacks Investment Research raised Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Tuesday, January 30th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $24.25.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.